ELEVAI Labs Expands Board of Directors

ELEVAI LABS, INC., a medical aesthetic biotechnology company specializing in physician-dispensed skincare, has announced the addition of Crystal Muilenburg as an independent member of the company’s Board of Directors.

Muilenburg brings more than two decades of experience in marketing, corporate communications, and public relations for global Fortune 500 companies and public-company start-ups. She will play a key role in supporting the ELEVAI management team as it commercializes ELEVAI’s flagship exosome product line while driving the market adoption for physician-dispensed topical exosomes.

“I’m thrilled to join ELEVAI as they establish a new segment of physician-dispensed skincare products harnessing topical exosomes,” said Muilenburg. “With a science-first approach, an industry-leading management team, and the market’s interest in the novel approach to skin leveraging the power of exosomes, ELEVAI’s future is bright.”

Most recently, Muilenburg served as chief marketing officer for Evolus where she led the re-launch of Jeuveau, a disruptor brand to BOTOX Cosmetic. Under Muilenburg’s leadership, Jeuveau became one of the fastest-growing neurotoxins in the United States and one of the top product launches in esthetics history.

Prior to Evolus, Muilenburg was head of global strategic marketing for Sienna Biopharmaceuticals, a publicly traded, clinical-stage medical dermatology company. Crystal also spent more than a decade at Allergan in various leadership roles in US and International marketing and communications where she gained significant FDA approval and commercial launch experience with the company’s flagship BOTOX franchise and leading esthetics brands.                     

“We are excited to welcome Crystal to ELEVAI’s Board,” said ELEVAI founder, Jordan R. Plews, Ph.D. “We believe her track record, accomplishments, and science-first approach will help propel ELEVAI in becoming the preferred topical exosome company as this segment continues to grow in interest and demand.”